Stapled Peptide Inhibitor Targets Amyloid-Beta Fibril Surfaces to Block Toxic Oligomer Formation
Helically constrained stapled peptides recognized amyloid-β fibril surfaces with submicromolar affinity (~0.75 μM) and effectively inhibited surface-mediated toxic oligomer formation.
Quick Facts
What This Study Found
Stapled helical peptides recognized the K16-E22 region of Aβ40 fibril surfaces and inhibited surface-mediated oligomerization. The best candidate achieved ~0.75 μM binding affinity through hydrophobic staple-fibril surface interactions.
Key Numbers
Helical peptide bound Aβ40 fibril surface K16-E22 region with micromolar affinity; blocked toxic oligomer formation.
How They Did This
Peptide synthesis with in-tether chiral center-induced helical stabilization. Binding affinity measurements. Extensive computational sampling revealing two distinct binding modes. Oligomerization inhibition assays.
Why This Research Matters
Most Alzheimer's drug approaches target soluble amyloid or prevent aggregation. Targeting the fibril surface — the actual platform that generates toxic oligomers — is a novel strategy that could complement existing approaches.
The Bigger Picture
The repeated failures of anti-amyloid drugs in Alzheimer's trials have pushed researchers to explore alternative targets. Fibril surfaces as oligomer generators represent a compelling new target, and stapled peptides provide the molecular tools to hit them.
What This Study Doesn't Tell Us
In vitro study — no cellular or animal model testing. The relationship between fibril surface-mediated oligomerization and Alzheimer's pathology in vivo needs validation. Peptide drug delivery to the brain remains a major challenge.
Questions This Raises
- ?Can these stapled peptides cross the blood-brain barrier to reach amyloid deposits?
- ?Would inhibiting fibril surface-mediated oligomerization reduce neurotoxicity in animal models?
- ?Could this approach be applied to other amyloid diseases like Parkinson's or type 2 diabetes?
Trust & Context
- Key Stat:
- ~0.75 μM binding affinity of the best stapled peptide inhibitor for amyloid-β fibril surfaces
- Evidence Grade:
- In vitro proof-of-concept with computational validation. Novel target approach but early-stage without cellular or animal testing.
- Study Age:
- Published in 2020. Stapled peptide approaches for neurodegenerative diseases continue to be explored.
- Original Title:
- Targeting the Amyloid-β Fibril Surface with a Constrained Helical Peptide Inhibitor.
- Published In:
- Biochemistry, 59(3), 290-296 (2020)
- Authors:
- Yang, Fadeng, Zhang, Wan, Jiang, Yixiang, Yin, Feng, Han, Wei, Li, Zigang
- Database ID:
- RPEP-05214
Evidence Hierarchy
Frequently Asked Questions
What are stapled peptides?
Stapled peptides are short protein fragments with a chemical 'staple' that locks them into their active helical shape, making them more stable, more potent, and potentially more drug-like than regular peptides.
Why target fibril surfaces instead of amyloid itself?
Recent research shows that amyloid fibril surfaces actively generate the toxic oligomers that damage brain cells. Blocking this surface activity could prevent toxicity even when fibrils are already present.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05214APA
Yang, Fadeng; Zhang, Wan; Jiang, Yixiang; Yin, Feng; Han, Wei; Li, Zigang. (2020). Targeting the Amyloid-β Fibril Surface with a Constrained Helical Peptide Inhibitor.. Biochemistry, 59(3), 290-296. https://doi.org/10.1021/acs.biochem.9b00800
MLA
Yang, Fadeng, et al. "Targeting the Amyloid-β Fibril Surface with a Constrained Helical Peptide Inhibitor.." Biochemistry, 2020. https://doi.org/10.1021/acs.biochem.9b00800
RethinkPeptides
RethinkPeptides Research Database. "Targeting the Amyloid-β Fibril Surface with a Constrained He..." RPEP-05214. Retrieved from https://rethinkpeptides.com/research/yang-2020-targeting-the-amyloid-fibril
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.